For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZKG865. CME/MOC/NCPD/AAPA/IPCE credit will be available until January 9, 2025.
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for American Cancer Society; Amgen Inc.; Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Servier.
Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company Limited; Transcenta; and Zymeworks Inc.
Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca; BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co, Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks Inc.
Co-Chair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co., Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Herbert L. Bonkovsky, MD - Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?
Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition
"Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH"
Chris A. Liacouras, MD - Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy
Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers
Evan S. Dellon, MD, MPH - Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options
Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies
Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
Ikuo Hirano, MD - On the Cusp of a New Era in Treatment for Eosinophilic Esophagitis: Expert Insights on the Latest Advances in Targeted Therapy
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
Create your
podcast in
minutes
It is Free
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast